A Neutral and Stable Macrocyclic Mn(II) Complex for MRI Tumor Visualization

ChemMedChem. 2022 Dec 16;17(24):e202200508. doi: 10.1002/cmdc.202200508. Epub 2022 Oct 27.

Abstract

A stable and inert amphiphilic Mn(II) complex based on a bisamide derivative of 1,4-DO2A (DO2A=tetraazacyclododecane-1,4-diacetic acid) was synthesized and its 1 H NMR relaxometric behavior was investigated as a function of the magnetic field strength, pH and temperature. The interaction with human serum albumin (HSA) was also studied via relaxometry showing a good relaxivity enhancement at low field (at 1T and 298 K the relaxivity increases from 4.5 mM-1 s-1 of the Mn(II)-complex to 14.0 mM-1 s-1 of the complex-HSA supramolecular adduct). In vivo biodistribution and MRI studies highlighted a rapid and mixed renal/liver elimination without spleen accumulation from healthy mice and good contrast enhancing properties in a breast tumor murine model. A comparison with a clinically approved Gd(III) agent (GdBOPTA, Multihance®) underlined that the proposed Mn(II) contrast agent gave comparable tumor contrast enhancement up to 3 hours post-injection.

Keywords: MRI; Manganese; contrast agent; relaxometry; tumor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Contrast Media* / chemistry
  • Humans
  • Magnetic Resonance Imaging
  • Manganese / chemistry
  • Mice
  • Neoplasms*
  • Serum Albumin, Human
  • Tissue Distribution

Substances

  • Contrast Media
  • Manganese
  • Serum Albumin, Human